Elisa S.
- Country
- Italy
- Department
- Oncologia
Research Overview
- Evaluation of Temozolomide and Irinotecan Consolidation in MGMT-Silenced, Microsatellite Stable Colorectal Cancer with Persistent Minimal Residual Disease
- Phase II Randomized Study of Panitumumab and Regorafenib Sequencing in RAS/BRAF Wild-Type Chemorefractory Metastatic Colorectal Cancer
- Evaluation of ctDNA Clearance in Stage III and High-Risk Stage II Resected Colon Cancer Using FOLFOXIRI, Trifluridine/Tipiracil, and Drug Combinations
Data & Insights
Has run more than one trial at 45 of 76 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in advanced therapeutic approaches for colorectal cancer, with particular focus on metastatic disease management and molecular targeted therapies.
- RAS/BRAF mutation analysis
- Circulating tumor DNA monitoring
- Post-operative treatment optimization
Their research extends to innovative treatment sequences and combination strategies for chemorefractory patients.
Hematologic and Gynecologic Oncology
The investigator conducts research in myelodysplastic syndromes and advanced ovarian cancer, exploring novel therapeutic approaches and maintenance strategies.
- HRD-positive ovarian cancer treatment
- Lower-risk MDS management
- Endometrial cancer therapies
Their work includes evaluation of targeted agents and immunotherapy combinations.
Diverse Therapeutic Areas
The investigator's expertise spans multiple specialized medical fields, including cholangiocarcinoma, psoriatic arthritis, and Crohn's disease.
- Neoadjuvant immunotherapy approaches
- Cardiac surgical interventions
- Inflammatory disease management
Research focuses on innovative therapeutic strategies across these varied conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.